Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Raised by Capital International Inc. CA

Key Points

• Capital International Inc. CA increased its stake in Alnylam by 5.3% to 75,638 shares, worth about $34.49 million, according to its most recent 13F filing.
• Alnylam missed the quarter's estimates with EPS of $1.25 (vs. $1.43 est.) and revenue of $1.10 billion (vs. $1.16 billion est.), though revenue was up 84.9% year‑over‑year.
• Analysts remain largely bullish — one Strong Buy, 22 Buys and five Holds — giving an average price target of $477.96 and a consensus rating of "Moderate Buy."

Capital International Inc. CA lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 75,638 shares of the biopharmaceutical company's stock after buying an additional 3,807 shares during the quarter. Capital International Inc. CA owned about 0.06% of Alnylam Pharmaceuticals worth $34,491,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $243,000. Geneos Wealth Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 372.3% in the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 175 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in Alnylam Pharmaceuticals by 50.8% in the second quarter. First Horizon Advisors Inc. now owns 187 shares of the biopharmaceutical company's stock worth $61,000 after purchasing an additional 63 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $30,000. Finally, Vestmark Advisory Solutions Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $567,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Analyst Ratings Changes

ALNY has been the subject of several analyst reports. Oppenheimer started coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an "outperform" rating and a $500.00 target price for the company. Bank of America reissued a "buy" rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Chardan Capital decreased their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a "buy" rating for the company in a report on Friday, February 13th. Stifel Nicolaus raised their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a "buy" rating in a research note on Thursday, December 11th. Finally, Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $477.96.

Alnylam Pharmaceuticals Trading Up 0.9%

Shares of Alnylam Pharmaceuticals stock opened at $323.53 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The company's fifty day simple moving average is $350.74 and its 200-day simple moving average is $413.17. The company has a market cap of $42.91 billion, a price-to-earnings ratio of 189.20 and a beta of 0.36. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the previous year, the company earned ($0.65) earnings per share. Alnylam Pharmaceuticals's revenue for the quarter was up 84.9% compared to the same quarter last year. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 2,780 shares of the business's stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the transaction, the executive vice president directly owned 57,465 shares in the company, valued at $20,852,324.55. The trade was a 4.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the company's stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total value of $848,055.70. Following the completion of the transaction, the executive vice president directly owned 21,264 shares of the company's stock, valued at approximately $7,874,697.12. This trade represents a 9.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 53,923 shares of company stock worth $18,072,087 over the last ninety days. Corporate insiders own 1.20% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.